Follow us : Twitter LinkedIn
Conseils en Propriété Industrielle / European Patent and Trademark Attorneys
Client Login
Home > Publications > Search for a publication

Search a publication

Title of Intellectual Property
Patents
European and Unitary Patent
US Patent
Trademark
European Union trademark
International Trademark
Design
Domain names
Software
Copyright
Theme
Health
Medtech
Patentability of Biological Material
Arbitration and Mediation
Contracts
Infringement
Regulation, Labelling
Data
Wine and Spirits
Pharmacy
Well-known TM, Dilution, Use
Accelerated Examination
European patent
Immunotherapy
PACTE Law
Biodiversity
Brexit
Biomarkers
Author name

Search result

4 publications

Protecting by patent a drug combining two known active ingredients: is it possible ?

By Aurélia VAVASSEUR, European and French Patent Attorney
A.Vavasseur.jpg More and more therapeutic treatments are based on the combination of two (or more) distinct active ingredients. It is possible to obtain patent protection for such a combination under certain conditions...
Published on: 30th Dec 2021

Pandemic and european patent application filings in the biomedical field

By Frédérique FAIVRE PETIT, Managing Partner
Faivre-Petit_search.jpg If the European Patent Office (EPO) notes a very slight decrease in the total number of European patent applications filed in 2020 (-0.7%), it nevertheless notes for this pandemic year a strong increase in these filings in the biomedical field.
Published on: 8th April 2021

Infringement and Medical Products

by Pierre BOUGEARD, French and European Trademark and Design Attorney
P.BOUGEARD.jpg Intended to combat the infringment of medical products and to protect public health, the Medicrime Convention entered into force on 1 January 2016.
Published on: 11th May 2016

Enantiomers – Revocation of a patent on enantiomer (-) for lack of enablement

By Francis Ahner, Partner and Anne Boutaric, European and French Patent Attorney
Recently, the validity of a patent claiming an enantiomer of a known racemic compound was discussed for the first time before the Paris Court (Tribunal de Grande Instance – 1st instance; decision issued on October 6th, 2009).
Published on: 22th Oct 2009